European & International Media

W.H.O. Warns That Pipeline for New Antibiotics Is Running Dry

The New York Times
In two new reports, the WHO says only government intervention can fix the broken market for new antimicrobial drugs.

READ MORE

Big pharma failing to invest in new antibiotics, says WHO

The Guardian
Big pharma continues to walk away from investment in new antibiotics and there are alarmingly few useful new drugs in the pipeline to deal with the worsening crisis of antibiotic resistance, according to the World Health Organization.

READ MORE
Denmark Raises Antibiotic-Free Pigs. Why Can’t the U.S.?

The New York Times

As use of antibiotics in livestock has soared globally, contributing to the rise of drug-resistant germs, Denmark, which ranks among the world’s top pork exporters, has proved that a country can build a thriving industry while sharply cutting back on antibiotic use in pigs.

Low Antibiotic Prices Dampen Industry Investment In Vital New Tools To Combat Superbugs – Says AMR Industry Alliance

Health Policy Watch

In this case, low market prices are thwarting efforts to bring promising new treatments to market, treatments needed to combat so-called "superbugs" – bacteria, viruses and parasites that are increasingly resistant to existing drug treatments.

Fighting antimicrobial resistance requires action on many fronts

Euractiv

Collaborations with health authorities and policymakers to explore and support initiatives that will strengthen the long-term sustainability of the antimicrobial product market, improve supply chain security, and reduce drug shortages, are necessary next steps.

Antibiotic resistance: Effect of climatic spike

DownToEarth

Climate change is a new trigger for antibiotic resistance. Global warming is increasing the pace of reproduction in bacteria and leading to the development of resistance.
Lack of new antibiotics threatens global efforts to contain drug-resistant infections

World Health Organization

According to the WHO, declining private investment and lack of innovation in the development of new antibiotics are undermining efforts to combat AMR.

Report on Antibacterial agents in clinical development – an analysis of the antibacterial clinical development pipeline

World Health Organization

The two reports reveal a weak antibiotics pipeline and R&D for antibiotics primarily driven by SME’s. They call on the pharmaceutical industry and governments to invest into developing innovative new medicines to contain drug-resistant infections.

European & International Organisations

Lack of antibiotics in low income countries 'worsening superbugs threat'

The Guardian

Many antibiotics are unavailable in poorer countries despite higher infection rates, exacerbating the threat of drug-resistant superbugs, according to a report to be presented to world leaders and the bosses of top pharmaceutical companies in Davos.

Antibiotic resistance nearly killed me. That’s why I’m raising awareness of it

Stat news

There are many reasons why people write about the looming threat of antibiotic resistance. Academics do it to share their research. Politicians and public health experts do it to show what’s working and what isn’t. I do it because getting an infection that nearly took my life is not something I want to see happen to anyone else.
Urgent health challenges for the next decade
World Health Organization

AMR is included in the list of urgent global health challenges released by the WHO, under the theme 'Protecting the medicines that protect us'.

READ MORE

2020 Antimicrobial Resistance Benchmark
Access to Medicine Foundation

The 2020 Antimicrobial Resistance Benchmark reveals signs of improvement in how pharmaceutical companies are tackling AMR, particularly when it comes to stewardship. However, progress on AMR is slow.

READ MORE

National Developments

Antimicrobial resistance: a priority research programme led by Inserm
Inserm

READ MORE

National Media

Resistant bacteria: WHO warns of shortage of new antibiotics
France Info

READ MORE

Superbacteria: WHO warns of shortage of new antibiotics
Le Soir

READ MORE

Antibiotic resistance: kick-off of the priority research programme!
Senior Actu

READ MORE
40 million euros for fighting antibiotic resistance
EDP Biologie

An "escape game" enables caregivers to improve the detection of antibiotic resistance
Tec Hopital

Sepsis bigger killer than cancer worldwide, study suggests
The Irish Times

New recommendations for antimicrobial-resistant bacteria's prevention and surveillance
EDP Biologie

Emerging Highly Resistant Bacteria: HCSP Updates Recommendations with Expanded Screening Conditions
Le Quotidien Du Medecin

Research: new breakthrough in battling resistance to antibiotics
The Brussels Times

Research and Scientific Studies
Antibiotic-resistance in Tanzania is an environmental problem

Washington States University Insider

Antibiotic-resistant bacteria are prevalent in people, wildlife and the water in northeastern Tanzania, but it’s not antibiotic use alone driving resistance. Instead, researchers at Washington State University found transmission of bacteria in the environment is the most important factor.

READ MORE

The antimicrobial crisis: enough advocacy, more action

The Lancet

Too little action has been taken to address the market failure in antibiotic development. 2020 marks the 30th anniversary of Davos, and the World Economic Forum will release a new manifesto to mark the occasion.

READ MORE

When not to start antibiotics: avoiding antibiotic overuse in the intensive care unit

Clinical Microbiology and Infection

Most intensive care unit (ICU) patients receive broad-spectrum antibiotics. While lifesaving in some, in others these treatments may be unnecessary and place patients at risk of antibiotic-associated harms.

READ MORE

(Internationalising the antibiotic research and development pipeline

The Lancet

(...) antibiotics remain a global resource without an international support structure that is commensurate to the risks from antibiotic-resistant infections and the long-term nature of required solutions.

READ MORE

You are receiving this publication as you have subscribed to the EPHA AMR Feed, which is published four times a year. If you want to receive other EPHA communications or change your mailing preferences, you can do so by clicking on the buttons below.

UPDATE YOUR MAILING PREFERENCES

UNSUBSCRIBE FROM EPHA COMMUNICATIONS

EPHA (AISBL) is the European Platform bringing together public health organisations representing health professionals, patients groups, health promotion and disease specific NGOs, academic groupings and other health associations. The European Public Health Alliance has received funding under an operating grant from the European Union's Health Programme (2014-2020). The content of this email represents the views of the author only and is his/her sole responsibility; it cannot be considered to reflect the views of the European Commission and/or the Consumers, Health, Agriculture and Food Executive Agency or any other body of the European Union. The European Commission and the Agency do not accept any responsibility for use that may be made of the information it contains. Transparency Register Number: 18941013532-08

Our mailing address is:
European Public Health Alliance AISBL, Rue de Trèves 49-51, Brussels 1000, Belgium